Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 10Lung Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 5Head and Neck Neoplasms 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Squamous Cell 5Neoplasm Metastasis 4Colorectal Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Hematologic Neoplasms 2Glioma 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unilateral HER2 Positive Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Cancers of the Head and Neck 1Solid Tumors 1

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × Afatinib × Clear all
NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡